Skip to main content
SpringerLink
Log in

Therapieoptionen beim hormonrefraktären Prostatakarzinom

  • Chapter
Pharmakotherapie in der Urologie

  • 60 Accesses

Zusammenfassung

Das Prostatakarzinom (PCa) ist mittlerweile der häufigste Tumor des Mannes und die zweithäufigste tumorbedingte Todesursache. Die überwiegende Mehrheit der Patienten ist mit einer Hormonentzugstherapie behandelt worden, die jedoch nach einem gewissen Zeitraum ihre therapeutische Effektivität verliert. Trotz der Häufigkeit dieser Erkrankung gibt es nach Tumorprogression unter Androgenablation keine etablierte Standardtherapie. Patienten mit einem ossär metastasierten Prostatakarzinom weisen im Mittel nach 12 bis 18 Monaten eine Progression in ein hormonrefraktäres Stadium (HRPC) auf. Indiesem Stadium beträgt die mittlere Überlebenszeit 12 Monate [18]. In den letzten Jahren hat sich aufgrund von Studienergebnissen das Verständnis des Pathomechanismus der Hormonunabhängigkeit grundlegend verändert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abell FL, Wilkes JD, Divers L (1995) Oral cyclophosphamide (CTX) for hormone refractory prostate cancer. Proc Amer Soc Clin Oncol 14: 646

    Google Scholar 

  2. Benson R, Hartley-Asp B (1990) Mechanism of action and clinical uses of estramustine. Cancer Invest 8: 375

    Article  PubMed  CAS  Google Scholar 

  3. Dawson NA (1993) Treatment of progressive metastatic prostate cancer. Oncology 7:17

    PubMed  CAS  Google Scholar 

  4. di Sant’ Agnese PA (1992) Neutoendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications. Cancer 70: 254

    Article  Google Scholar 

  5. Ferro MA, Gillatt D, Symes MO et al. (1989) High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate specific antigen to monitor response. Urology 34: 134

    Article  PubMed  CAS  Google Scholar 

  6. Fowler JE, Whitmore WF jr. (1981) The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 126: 372

    PubMed  Google Scholar 

  7. Fowler JE, Pandey P, Seaver LE et al. (1995) Prostate specific antigen after gonadal withdrawal and deferred flutamide treatment. J Urol 154: 448

    Article  PubMed  Google Scholar 

  8. Horton J, Rosenbaum C, Cummings FJ (1988) Tamoxifen in advanced prostate cancer: an ECOG pilot study. Prostate 12: 173

    Article  PubMed  CAS  Google Scholar 

  9. Hudes G (1997) Estramustine-based chemotherapy. Semin Urol Oncol 15: 13

    PubMed  CAS  Google Scholar 

  10. Hudes G, Einhorn L, Ross E et al. (1999) Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 17: 3160

    PubMed  CAS  Google Scholar 

  11. Joyce R, Fenton MA, Rode P et al. (1998) High-dose bicalutamidefor androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 159: 149

    Article  PubMed  CAS  Google Scholar 

  12. Kantoff PW, Halabi S, Conaway M, Picus J et al. (1996) in Hydrocortisone with and without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B9182 study. 17: 2506

    Google Scholar 

  13. Kelly WK (1998) Endocrine withdrawal syndrome and ist relevance to the management of hormone refractoty prostate cancer. Eur Urol 34 (Suppl 4): 18

    Article  PubMed  Google Scholar 

  14. Kelly WK, Scher HI (1993) Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Urol 149; 607

    PubMed  CAS  Google Scholar 

  15. Kelly WK, Scher HI, Mazumadar M et al. (1993) Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11: 607

    PubMed  CAS  Google Scholar 

  16. Klugo RC, Farah RN, Cerny JC (1981) Bilateral orchiectomy for carcinoma of the prostate: response of serum testosterone and clinical response to estrogen therapy. Urology 17: 49

    Article  PubMed  CAS  Google Scholar 

  17. Kreis W (1995) Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer. Cancer Invest 13: 296

    Article  PubMed  CAS  Google Scholar 

  18. Mahler C, Denis L (1995) Hormone refractory disease. Semin Surg Oncol 11:77

    Article  PubMed  CAS  Google Scholar 

  19. Maulard-Dardux C, Dufour B, Hennequin C et al. (1997) Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer 77: 1144

    Article  Google Scholar 

  20. Oh WK, Kantoff PW (1998) Management of hormone refractory prostate cancer: current status and future prospects. J Urol 160: 1220

    Article  PubMed  CAS  Google Scholar 

  21. Orlando M, Chacon M, Salum G et al. (2000) Low-dose oral fosfestrol is highly active in hormon-refractory prostate cancer. Ann Oncol 11: 177

    Article  PubMed  CAS  Google Scholar 

  22. Petrylak DP (1999) Chemotherapy for advanced hormone refractory prostate cancer. Urology 54 (Suppl 6a): 31

    Article  Google Scholar 

  23. Pienta KJ, Redman B, Hussein M et al. (1994) Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12: 2005

    PubMed  CAS  Google Scholar 

  24. Raghavan D, Cox K, Pearson BS et al. (1993) Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol 72: 625

    Article  PubMed  CAS  Google Scholar 

  25. Rochlitz CF, Damon LE, Russi MB et al. (1988) Cytotoxicity of ketokonazole in malignant cell lines. Cancer Chemother Pharmacol 21: 319

    Article  PubMed  CAS  Google Scholar 

  26. Sartor O, Cooper M, Weinberger M et al. (1994) Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of “hormone-refracrtory” prostate cancer. J Natl Cancer Inst 86: 222

    Article  PubMed  CAS  Google Scholar 

  27. Schellhammer P, Venner P, Haas G et al. (1997) Prostate specific antigen decreases after withdrawal of androgen therapy with bicalutamide or flutamide in patients receivin combined androgen blockade. J Urol 157:1731

    Article  PubMed  CAS  Google Scholar 

  28. Scher HI, Liebertz C, Kelly WK et al. (1997) Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 15: 2928

    PubMed  CAS  Google Scholar 

  29. Small EJ, Baron AD, Fippin L et al. (1997) Ketokonazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 159: 1204

    Google Scholar 

  30. Smith DC, Dunn RL, Srawderman MS et al.(1998) Change in serum prostate-.specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16: 1835

    PubMed  CAS  Google Scholar 

  31. Tannock IF, Osoba D, Stockier MR et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a canadian randomized trial with palliative end points. J Clin Oncol 14: 1756

    PubMed  CAS  Google Scholar 

  32. Taplin ME, Bubley GJ, Shuster TD et al. (1995) Mutation of the androgen-receptor gene in metastatic prostate cancer. N Engl J Med 332: 1393

    Article  PubMed  CAS  Google Scholar 

  33. Wilding G (1995) Endocrine control of prostate cancer. Canvcer Sury 23: 43

    CAS  Google Scholar 

Download references

Authors
  1. S. Machtens
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Urologische Klinik und Poliklinik, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Michael C. Truss , Christian G. Stief , Stefan Machtens  & Udo Jonas (Direktor), ,  &  (Direktor)

  2. Zentrum Anästhesiologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Till Wagner

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Machtens, S. (2002). Therapieoptionen beim hormonrefraktären Prostatakarzinom. In: Truss, M.C., Stief, C.G., Machtens, S., Jonas, U., Wagner, T. (eds) Pharmakotherapie in der Urologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09273-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-09273-6_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-41519-0

  • Online ISBN: 978-3-662-09273-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation